Navigation Links
FDA Advisory Panel Votes Favorably on the First of Its Kind Hybrid Hearing Device from Cochlear
Date:11/11/2013

CENTENNIAL, Colo., Nov. 11, 2013 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today that an advisory committee to the US Food and Drug Administration (FDA) voted favorably on the Cochlear™ Nucleus® Hybrid™ L24 Implant System. This is a first of its kind system designed for the treatment of adults with severe to profound sensorineural hearing loss in the high frequencies and normal to only mild hearing loss in the low frequencies, often referred to as "ski-slope" hearing loss. The panel, comprised of leading physicians and researchers, voted in favor of the new Hybrid device based on substantial clinical evidence demonstrating the safety and efficacy of the Nucleus Hybrid System in patients who met the candidacy criteria. The FDA is not bound by the recommendations of its advisory committees, but will consider the guidance during the final review of the new Hybrid device.

(Logo: http://photos.prnewswire.com/prnh/20130531/LA23942)

"We are pleased with the panel's vote for the Nucleus Hybrid System," said Chris Smith, President of Cochlear Americas. "The notion of hybrid hearing is truly a novel one that addresses an unmet need for people with hearing loss by bridging the gap between hearing aids and cochlear implants. This first-of-its-kind technology consists of a unique combination of solutions to overcome high frequency hearing loss, which impairs a person's ability to hear voices clearly and understand speech in noise. This positive recommendation is an important first step to giving thousands of patients the opportunity to hear much better than was possible even with the most advanced hearing aids."

The Nucleus Hybrid System combines the natural hearing via acoustic amplification of low frequencies with the electrical stimulation of a cochlear implant for high frequencies in one device. It is designed to deliver patients superior quality and clarity of sound in even the most difficult hearing situations, especially hearing in noisy environments.

"The Nucleus Hybrid System is a technological breakthrough when it comes to treating patients with hearing loss," said Bruce J. Gantz, M.D., Head of the Department of Otolaryngology – Head and Neck Surgery at the University of Iowa Carver College of Medicine and Hybrid System clinical investigator. "This device will open the doors to a whole new way of hearing both acoustically and electrically for those patients who cannot be treated effectively today with hearing aids."

About Cochlear
Cochlear is the global leader in implantable hearing solutions. It has a dedicated global team of more than 2,700 people who deliver the gift of sound to those with hearing loss in over 100 countries. Its vision is to connect people, young and old, to a world of sound by offering life enhancing hearing solutions.

The Cochlear promise of "Hear now. And always" embodies the company's commitment to providing its recipients with their best possible hearing performance today and for the rest of their lives. For over 30 years Cochlear has helped hundreds of thousands of people either hear for the first time or reconnect them to their families, friends, workplaces and communities.

For more information, visit Cochlear.com.


'/>"/>
SOURCE Cochlear Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
4. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
5. Generex Augments Antigen Express Scientific Advisory Board
6. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
7. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
8. Marken Announces Global Advisory Board
9. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
10. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... 22, 2019 , ... Americans can save more money on generic drugs at ... compared prices on the top-selling generic drugs. Eighty-eight percent of the top prescribed generics ... far lower at Canadian and other international online pharmacies than in the ...
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... Vib has announced the release of The ... about CBD vaping for beginners and explains some of the benefits it offers. ... quit smoking’ the long-term vaping community is finally realizing that there are lots of hidden ...
(Date:5/22/2019)... ... May 22, 2019 , ... Two years ago ... a changing culture of risk-based quality management (RBQM) in the pharmaceutical industry. Both ... existing clinical trial portfolios. Cloud-based technology offers several advantages to ensuring companies are ...
Breaking Medicine Technology:
(Date:5/23/2019)... ... May 23, 2019 , ... In the U.S. in ... 1,092 embryo transfer procedures, the last step in the in vitro fertilization (IVF) process. ... five years earlier.[1] Dr. Mark P. Trolice, Director of Fertility CARE: The IVF ...
(Date:5/23/2019)... (PRWEB) , ... May 23, 2019 , ... ... and New York Medical College, Altus Assessments has published new research in an ... CASPer, can have the potential of increasing the racial and ethnic diversity of ...
(Date:5/23/2019)... ... , ... Arasan Chip Systems announces the immediate availability its MIPI CSI-2 v2.1 ... supporting speeds of upto 3.5 Gsps symbol rate per lane (equivalent to 7.98 Gbps ... rate per lane. With this latest CSI IP v2.1, provides a Total CSI IP ...
(Date:5/23/2019)... ... ... Join Dr. Ashok Srivastava, CEO & CMO at ClinFomatrix and CEO at Cure ... Systems, Inc. , in a live webinar on Tuesday, June 11, 2019 ... patient profiles. Together, the two speakers bring years of experience in drug development, medical ...
(Date:5/23/2019)... (PRWEB) , ... May 23, 2019 , ... ... and Potomac Pathways are joining forces to turn the tide in the rising ... Potomac Programs and signifies Embark’s commitment to community, outpatient, and home-based care. Potomac’s ...
Breaking Medicine News(10 mins):